scPharmaceuticals (SCPH) Projected to Post Quarterly Earnings on Wednesday

scPharmaceuticals (NASDAQ:SCPH) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $12.08 million for the quarter.

scPharmaceuticals Stock Performance

Shares of SCPH opened at $3.29 on Wednesday. The business’s 50 day moving average is $3.40 and its two-hundred day moving average is $3.97. scPharmaceuticals has a 52-week low of $3.08 and a 52-week high of $6.20. The firm has a market cap of $164.63 million, a price-to-earnings ratio of -1.73 and a beta of 0.11. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66.

Wall Street Analysts Forecast Growth

SCPH has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research report on Monday. Craig Hallum cut their target price on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.